Crocs, Inc. vs Revolution Medicines Inc. Common Stock — how do they compare? Crocs, Inc. trades at $117.73 (market cap $5.60B), while Revolution Medicines Inc. Common Stock trades at $191.91 (market cap $40.32B). The key difference: Revolution Medicines Inc. Common Stock is far larger — about 7.2× Crocs, Inc.'s market cap, and Revolution Medicines Inc. Common Stock is trading nearer its 52-week high, Crocs, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crocs, Inc. for 96 Days and Revolution Medicines Inc. Common Stock for 0 Days on average.
| CROX | RVMD | |
|---|---|---|
Market Cap | $5.60B | $40.32B |
Volume | 1,026,773 | 4,855,734 |
Sector | Consumer Cyclical | Health |
52-Week High | $141.19 | $221.15 |
52-Week Low | $73.39 | $47.50 |
Typical Hold Time | 96 Days | 0 Days |
Enterprise Value | $7.12B | $37.02B |
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $115.20, down 4.18% amid bearish technical signals, though recent earnings beats and a 51% analyst buy rating suggest underlying strength. The stock shows attractive valuation with a P/E of 10.37 and strong profitability metrics including 57.47% gross margin and 42.3% ROE. Management is focusing on product innovation and HEYDUDE brand reset to drive growth.
Despite near-term price pressure, CROX offers value with consensus price target of $136.78 (19% upside). Risks include recent net income decline to -$81M and competitive pressures in footwear. The company's cash flow generation and brand positioning support long-term recovery potential.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →